Ponatinib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase

Trial Profile

Ponatinib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Dec 2016 Results from this and other five studies presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 13 May 2016 Status changed from completed to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top